Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008: Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78. Free full-text

Ovarian Neoplasms

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 101 articles: HTML format

Single Articles

June 2008
1. SOEGAARD M , Kjaer SK, Cox M, Wozniak E, et al
   BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark.
   Clin Cancer Res. 2008;14:3761-7.
   PubMed     Related articles    Abstract available
   
   
   
2. BANZATO A , Bobisse S, Rondina M, Renier D, et al
   A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity.
   Clin Cancer Res. 2008;14:3598-606.
   PubMed     Related articles    Abstract available
   
   
   
3. TSURUTA Y , Pereboeva L, Breidenbach M, Rein DT, et al
   A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
   Clin Cancer Res. 2008;14:3582-8.
   PubMed     Related articles    Abstract available
   
   
   
4. WOLOSZYNSKA-READ A , Mhawech-Fauceglia P, Yu J, Odunsi K, et al
   Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer.
   Clin Cancer Res. 2008;14:3283-90.
   PubMed     Related articles    Abstract available
   
   
   May 2008
5. ISHIBASHI M , Nakayama K, Yeasmin S, Katagiri A, et al
   A BTB/POZ Gene, NAC-1, a Tumor Recurrence-Associated Gene, as a Potential Target for Taxol Resistance in Ovarian Cancer.
   Clin Cancer Res. 2008;14:3149-55.
   PubMed     Related articles    Abstract available
   
   
   
6. DUNCAN TJ , Al-Attar A, Rolland P, Scott IV, et al
   Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
   Clin Cancer Res. 2008;14:3030-5.
   PubMed     Related articles    Abstract available
   
   
   
7. MILNE RL , Osorio A, Cajal TR, Vega A, et al
   The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain.
   Clin Cancer Res. 2008;14:2861-9.
   PubMed     Related articles    Abstract available
   
   
   
8. DIEFENBACH CS , Gnjatic S, Sabbatini P, Aghajanian C, et al
   Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission.
   Clin Cancer Res. 2008;14:2740-2748.
   PubMed     Related articles    Abstract available
   
   
   April 2008
9. EGORIN MJ
   Population pharmacokinetc/pharmacodynamic modeling of Paclitaxel and Carboplatin in ovarian cancer.
   Clin Cancer Res. 2008;14:2517.
   PubMed     Related articles   
   
   
   March 2008
10. MEZZANZANICA D , Fabbi M, Bagnoli M, Staurengo S, et al
    Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients.
    Clin Cancer Res. 2008;14:1726-1733.
    PubMed     Related articles    Abstract available
    
    
    February 2008
11. WALSH MD , Cummings MC, Buchanan DD, Dambacher WM, et al
    Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients.
    Clin Cancer Res. 2008;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
12. SONG H , Hogdall E, Ramus SJ, Dicioccio RA, et al
    Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.
    Clin Cancer Res. 2008;14:1090-5.
    PubMed     Related articles    Abstract available
    
    
    
13. VISINTIN I , Feng Z, Longton G, Ward DC, et al
    Diagnostic Markers for Early Detection of Ovarian Cancer.
    Clin Cancer Res. 2008;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
14. GAGNON A , Kim JH, Schorge JO, Ye B, et al
    Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients.
    Clin Cancer Res. 2008;14:764-771.
    PubMed     Related articles    Abstract available
    
    
    
15. HEFLER LA , Concin N, Hofstetter G, Marth C, et al
    Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.
    Clin Cancer Res. 2008;14:710-4.
    PubMed     Related articles    Abstract available
    
    
    January 2008
16. BARTEL F , Jung J, Bohnke A, Gradhand E, et al
    Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival.
    Clin Cancer Res. 2008;14:89-96.
    PubMed     Related articles    Abstract available
    
    
    December 2007
17. QUINN JE , James CR, Stewart GE, Mulligan JM, et al
    BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy.
    Clin Cancer Res. 2007;13:7413-20.
    PubMed     Related articles    Abstract available
    
    
    
18. JACKSON D , Craven RA, Hutson RC, Graze I, et al
    Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Clin Cancer Res. 2007;13:7370-9.
    PubMed     Related articles    Abstract available
    
    
    
19. CANNISTRA SA
    BRCA-1 in Sporadic Epithelial Ovarian Cancer: Lessons Learned from the Genetics of Hereditary Disease.
    Clin Cancer Res. 2007;13:7225-7.
    PubMed     Related articles   
    
    
    
20. WITHAM J , Valenti MR, De-Haven-Brandon AK, Vidot S, et al
    The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin.
    Clin Cancer Res. 2007;13:7191-8.
    PubMed     Related articles    Abstract available
    
    
    
21. ZHENG Y , Katsaros D, Shan SJ, de la Longrais IR, et al
    A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
    Clin Cancer Res. 2007;13:6984-92.
    PubMed     Related articles    Abstract available
    
    
    
22. YANG T , Wall EM, Milne K, Theiss P, et al
    CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism.
    Clin Cancer Res. 2007;13:7172-80.
    PubMed     Related articles    Abstract available
    
    
    November 2007
23. ANNUNZIATA CM , Kleinberg L, Davidson B, Berner A, et al
    BAG-4/SODD and Associated Antiapoptotic Proteins Are Linked to Aggressiveness of Epithelial Ovarian Cancer.
    Clin Cancer Res. 2007;13:6585-6592.
    PubMed     Related articles    Abstract available
    
    
    
24. SONG J , Shih IM, Salani R, Chan DW, et al
    Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients.
    Clin Cancer Res. 2007;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
25. JOERGER M , Huitema AD, Richel DJ, Dittrich C, et al
    Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Grou
    Clin Cancer Res. 2007;13:6410-6418.
    PubMed     Related articles    Abstract available
    
    
    
26. HAMA Y , Urano Y, Koyama Y, Gunn AJ, et al
    A Self-Quenched Galactosamine-Serum Albumin-RhodamineX Conjugate: A "Smart" Fluorescent Molecular Imaging Probe Synthesized with Clinically Applicable Material for Detecting Peritoneal Ovarian Cancer Metastases.
    Clin Cancer Res. 2007;13:6335-6343.
    PubMed     Related articles    Abstract available
    
    
    October 2007
27. KULKARNI AA , Loddo M, Leo E, Rashid M, et al
    DNA Replication Licensing Factors and Aurora Kinases are Linked to Aneuploidy and Clinical Outcome in Epithelial Ovarian Carcinoma.
    Clin Cancer Res. 2007;13:6153-6161.
    PubMed     Related articles    Abstract available
    
    
    
28. O'CONNOR JP , Jayson GC, Jackson A, Ghiorghiu D, et al
    Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma.
    Clin Cancer Res. 2007;13:6130-5.
    PubMed     Related articles    Abstract available
    
    
    
29. SHARMA S , Tammela J, Wang X, Arnouk H, et al
    Characterization of a Putative Ovarian Oncogene, Elongation Factor 1{alpha}, Isolated by Panning a Synthetic Phage Display Single-Chain Variable Fragment Library with Cultured Human Ovarian Cancer Cells.
    Clin Cancer Res. 2007;13:5889-96.
    PubMed     Related articles    Abstract available
    
    
    
30. FREEDMAN RS , Wang E, Voiculescu S, Patenia R, et al
    Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer.
    Clin Cancer Res. 2007;13:5736-5744.
    PubMed     Related articles    Abstract available
    
    
    
31. GUAN Y , Kuo WL, Stilwell JL, Takano H, et al
    Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer.
    Clin Cancer Res. 2007;13:5745-55.
    PubMed     Related articles    Abstract available
    
    
    September 2007
32. MEREDITH RF , Buchsbaum DJ, Alvarez RD, Lobuglio AF, et al
    Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
    Clin Cancer Res. 2007;13:5643s-5s.
    PubMed     Related articles    Abstract available
    
    
    
33. ZHANG L , Huang J, Yang N, Greshock J, et al
    Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
    Clin Cancer Res. 2007;13:5314-21.
    PubMed     Related articles    Abstract available
    
    
    
34. HASSAN R , Bullock S, Premkumar A, Kreitman RJ, et al
    Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers.
    Clin Cancer Res. 2007;13:5144-9.
    PubMed     Related articles    Abstract available
    
    
    August 2007
35. GORRINGE KL , Jacobs S, Thompson ER, Sridhar A, et al
    High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications.
    Clin Cancer Res. 2007;13:4731-9.
    PubMed     Related articles    Abstract available
    
    
    
36. BEDROSIAN I , Lee C, Tucker SL, Palla SL, et al
    Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy.
    Clin Cancer Res. 2007;13:4800-6.
    PubMed     Related articles    Abstract available
    
    
    
37. VAN HOLSBEKE C , Van Calster B, Valentin L, Testa AC, et al
    External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the international ovarian tumor analysis group.
    Clin Cancer Res. 2007;13:4440-7.
    PubMed     Related articles    Abstract available
    
    
    
38. MCINTOSH MW , Liu Y, Drescher C, Urban N, et al
    Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma.
    Clin Cancer Res. 2007;13:4422-4428.
    PubMed     Related articles    Abstract available
    
    
    July 2007
39. MABUCHI S , Altomare DA, Cheung M, Zhang L, et al
    RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model.
    Clin Cancer Res. 2007;13:4261-70.
    PubMed     Related articles    Abstract available
    
    
    
40. DUNCAN TJ , Rolland P, Deen S, Scott IV, et al
    Loss of IFN{gamma} Receptor Is an Independent Prognostic Factor in Ovarian Cancer.
    Clin Cancer Res. 2007;13:4139-45.
    PubMed     Related articles    Abstract available
    
    
    
41. LANDEN CN JR , Lin YG, Immaneni A, Deavers MT, et al
    Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients.
    Clin Cancer Res. 2007;13:4098-104.
    PubMed     Related articles    Abstract available
    
    
    
42. LASSMANN S , Shen Y, Jutting U, Wiehle P, et al
    Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy.
    Clin Cancer Res. 2007;13:4083-91.
    PubMed     Related articles    Abstract available
    
    
    
43. SMITH KL , Adank M, Kauff N, Lafaro K, et al
    BRCA mutations in women with ductal carcinoma in situ.
    Clin Cancer Res. 2007;13:4306-10.
    PubMed     Related articles    Abstract available
    
    
    
44. LU C , Kamat AA, Lin YG, Merritt WM, et al
    Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
    Clin Cancer Res. 2007;13:4209-17.
    PubMed     Related articles    Abstract available
    
    
    
45. FORSTER M , Kaye S, Oza A, Sklenar I, et al
    A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
    Clin Cancer Res. 2007;13:4178-84.
    PubMed     Related articles    Abstract available
    
    
    
46. SABBATINI PJ , Ragupathi G, Hood C, Aghajanian CA, et al
    Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.
    Clin Cancer Res. 2007;13:4170-7.
    PubMed     Related articles    Abstract available
    
    
    
47. BURGES A , Wimberger P, Kumper C, Gorbounova V, et al
    Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I/II Study.
    Clin Cancer Res. 2007;13:3899-3905.
    PubMed     Related articles    Abstract available
    
    
    
48. YOUNG TW , Rosen DG, Mei FC, Li N, et al
    Up-regulation of Tumor Susceptibility Gene 101 Conveys Poor Prognosis through Suppression of p21 Expression in Ovarian Cancer.
    Clin Cancer Res. 2007;13:3848-54.
    PubMed     Related articles    Abstract available
    
    
    
49. SCHULTES BC , Smith LM, Nicodemus CF
    Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Clin Cancer Res. 2007;13:4026.
    PubMed     Related articles   
    
    
    June 2007
50. SMYTH JF , Gourley C, Walker G, Mackean MJ, et al
    Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
    Clin Cancer Res. 2007;13:3617-22.
    PubMed     Related articles    Abstract available
    
    
    
51. ROLLAND P , Deen S, Scott I, Durrant L, et al
    Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.
    Clin Cancer Res. 2007;13:3591-6.
    PubMed     Related articles    Abstract available
    
    
    
52. GOYENECHE AA , Caron RW, Telleria CM
    Mifepristone Inhibits Ovarian Cancer Cell Growth In vitro and In vivo.
    Clin Cancer Res. 2007;13:3370-9.
    PubMed     Related articles    Abstract available
    
    
    
53. LIN YG , Kunnumakkara AB, Nair A, Merritt WM, et al
    Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-{kappa}B Pathway.
    Clin Cancer Res. 2007;13:3423-30.
    PubMed     Related articles    Abstract available
    
    
    May 2007
54. ZIGHELBOIM I , Goodfellow PJ, Schmidt AP, Walls KC, et al
    Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers.
    Clin Cancer Res. 2007;13:2882-2889.
    PubMed     Related articles    Abstract available
    
    
    
55. TSURUTA Y , Pereboeva L, Glasgow JN, Rein DT, et al
    A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus {sigma}1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor-Independent Pathway.
    Clin Cancer Res. 2007;13:2777-2783.
    PubMed     Related articles    Abstract available
    
    
    April 2007
56. LAMBECK AJ , Crijns AP, Leffers N, Sluiter WJ, et al
    Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7.
    Clin Cancer Res. 2007;13:2385-2391.
    PubMed     Related articles    Abstract available
    
    
    
57. BARDELLA C , Dettori D, Olivero M, Coltella N, et al
    The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo.
    Clin Cancer Res. 2007;13:2191-8.
    PubMed     Related articles    Abstract available
    
    
    March 2007
58. DORN J , Schmitt M, Kates R, Schmalfeldt B, et al
    Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
    Clin Cancer Res. 2007;13:1742-8.
    PubMed     Related articles    Abstract available
    
    
    
59. DANG Y , Knutson KL, Goodell V, dela Rosa C, et al
    Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Clin Cancer Res. 2007;13:1883-91.
    PubMed     Related articles    Abstract available
    
    
    
60. WIEDENMANN N , Valdecanas D, Hunter N, Hyde S, et al
    130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
    Clin Cancer Res. 2007;13:1868-74.
    PubMed     Related articles    Abstract available
    
    
    
61. JAMIESON D , Wilson K, Pridgeon S, Margetts JP, et al
    NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism.
    Clin Cancer Res. 2007;13:1584-90.
    PubMed     Related articles    Abstract available
    
    
    
62. WALKER G , Macleod K, Williams AR, Cameron DA, et al
    Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer.
    Clin Cancer Res. 2007;13:1438-44.
    PubMed     Related articles    Abstract available
    
    
    
63. GARG M , Chaurasiya D, Rana R, Jagadish N, et al
    Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Clin Cancer Res. 2007;13:1421-8.
    PubMed     Related articles    Abstract available
    
    
    February 2007
64. HEFLER LA , Mustea A, Konsgen D, Concin N, et al
    Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer.
    Clin Cancer Res. 2007;13:898-901.
    PubMed     Related articles    Abstract available
    
    
    January 2007
65. KNOGLER K , Grunberg J, Zimmermann K, Cohrs S, et al
    Copper-67 radioimmunotherapy and growth inhibition by anti-l1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
    Clin Cancer Res. 2007;13:603-11.
    PubMed     Related articles    Abstract available
    
    
    
66. MEINHOLD-HEERLEIN I , Bauerschlag D, Zhou Y, Sapinoso LM, et al
    An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
    Clin Cancer Res. 2007;13:458-66.
    PubMed     Related articles    Abstract available
    
    
    
67. FISHEL ML , He Y, Smith ML, Kelley MR, et al
    Manipulation of Base Excision Repair to Sensitize Ovarian Cancer Cells to Alkylating Agent Temozolomide.
    Clin Cancer Res. 2007;13:260-267.
    PubMed     Related articles    Abstract available
    
    
    
68. REIMER D , Sadr S, Wiedemair A, Stadlmann S, et al
    Clinical Relevance of E2F Family Members in Ovarian Cancer--An Evaluation in a Training Set of 77 Patients.
    Clin Cancer Res. 2007;13:144-51.
    PubMed     Related articles    Abstract available
    
    
    December 2006
69. SALVO VA , Boue SM, Fonseca JP, Elliott S, et al
    Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis.
    Clin Cancer Res. 2006;12:7159-64.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
70. SUROWIAK P , Materna V, Kaplenko I, Spaczynski M, et al
    ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome.
    Clin Cancer Res. 2006;12:7149-58.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
71. WILLIAMS LH , Choong D, Johnson SA, Campbell IG, et al
    Genetic and Epigenetic Analysis of CHEK2 in Sporadic Breast, Colon, and Ovarian Cancers.
    Clin Cancer Res. 2006;12:6967-72.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    November 2006
72. TSUDA N , Ishiyama S, Li Y, Ioannides CG, et al
    Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells.
    Clin Cancer Res. 2006;12:6557-6564.
    PubMed     Related articles    Abstract available
    
    
    October 2006
73. LUDWIG AH , Kupryjanczyk J
    Does MDR-1 G2677T/A Polymorphism Really Associate with Ovarian Cancer Response to Paclitaxel Chemotherapy?
    Clin Cancer Res. 2006;12:6204.
    PubMed     Related articles   
    
    
    
74. HASEGAWA K , Nakamura T, Harvey M, Ikeda Y, et al
    The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer.
    Clin Cancer Res. 2006;12:6170-6178.
    PubMed     Related articles    Abstract available
    
    
    
75. KERSHAW MH , Westwood JA, Parker LL, Wang G, et al
    A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
    Clin Cancer Res. 2006;12:6106-15.
    PubMed     Related articles    Abstract available
    
    
    
76. JIANG M , Shi W, Zhang Q, Wang X, et al
    Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.
    Clin Cancer Res. 2006;12.
    PubMed     Related articles    Abstract available
    
    
    
77. DAVIDSON B , Zhang Z, Kleinberg L, Li M, et al
    Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
    Clin Cancer Res. 2006;12:5944-50.
    PubMed     Related articles    Abstract available
    
    
    September 2006
78. SABBATINI P , Dupont J, Aghajanian C, Derosa F, et al
    Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Clin Cancer Res. 2006;12:5503-10.
    PubMed     Related articles    Abstract available
    
    
    
79. HAHN SM , Putt ME, Metz J, Shin DB, et al
    Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.
    Clin Cancer Res. 2006;12:5464-70.
    PubMed     Related articles    Abstract available
    
    
    
80. OGURA T , Kobayashi H, Ueoka Y, Okugawa K, et al
    Adenovirus-Mediated Calponin h1 Gene Therapy Directed against Peritoneal Dissemination of Ovarian Cancer: Bifunctional Therapeutic Effects on Peritoneal Cell Layer and Cancer Cells.
    Clin Cancer Res. 2006;12:5216-23.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
81. DUAN Z , Foster R, Bell DA, Mahoney J, et al
    Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Clin Cancer Res. 2006;12:5055-63.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    August 2006
82. HALDER J , Kamat AA, Landen CN Jr, Han LY, et al
    Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
    Clin Cancer Res. 2006;12:4916-24.
    PubMed     Related articles    Abstract available
    
    
    July 2006
83. MARSH S , King CR, McLeod HL, Paul J, et al
    ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer.
    Clin Cancer Res. 2006;12:4127-9.
    PubMed     Related articles       Free Full Text
    
    
    June 2006
84. DIFEO A , Narla G, Hirshfeld J, Camacho-Vanegas O, et al
    Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination.
    Clin Cancer Res. 2006;12:3730-9.
    PubMed     Related articles    Abstract available
    
    
    
85. CAMPBELL IG , Phillips WA, Choong DY
    Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km23 in Primary Ovarian, Breast, and Colorectal Cancers.
    Clin Cancer Res. 2006;12:3713-3715.
    PubMed     Related articles    Abstract available
    
    
    May 2006
86. WEI SH , Balch C, Paik HH, Kim YS, et al
    Prognostic DNA methylation biomarkers in ovarian cancer.
    Clin Cancer Res. 2006;12:2788-94.
    PubMed     Related articles    Abstract available
    
    
    
87. FERRANDINA G , Zannoni GF, Martinelli E, Paglia A, et al
    Class III {beta}-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients.
    Clin Cancer Res. 2006;12:2774-9.
    PubMed     Related articles    Abstract available
    
    
    April 2006
88. LU Z , Luo RZ, Peng H, Rosen DG, et al
    Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer.
    Clin Cancer Res. 2006;12:2404-13.
    PubMed     Related articles    Abstract available
    
    
    
89. POPADIUK CM , Xiong J, Wells MG, Andrews PG, et al
    Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
    Clin Cancer Res. 2006;12:2216-23.
    PubMed     Related articles    Abstract available
    
    
    
90. SCHOLLER N , Crawford M, Sato A, Drescher CW, et al
    Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers.
    Clin Cancer Res. 2006;12:2117-2124.
    PubMed     Related articles    Abstract available
    
    
    
91. RICE JR , Gerberich JL, Nowotnik DP, Howell SB, et al
    Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Clin Cancer Res. 2006;12.
    PubMed     Related articles    Abstract available
    
    
    March 2006
92. HASEGAWA K , Pham L, O'connor MK, Federspiel MJ, et al
    Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Clin Cancer Res. 2006;12:1868-75.
    PubMed     Related articles    Abstract available
    
    
    
93. CHAN JK , Hamilton CA, Cheung MK, Karimi M, et al
    Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Clin Cancer Res. 2006;12:1859-67.
    PubMed     Related articles    Abstract available
    
    
    
94. KAMAT AA , Fletcher M, Gruman LM, Mueller P, et al
    The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.
    Clin Cancer Res. 2006;12:1707-1714.
    PubMed     Related articles    Abstract available
    
    
    
95. POURGHOLAMI MH , Yan Cai Z, Lu Y, Wang L, et al
    Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Clin Cancer Res. 2006;12:1928-35.
    PubMed     Related articles    Abstract available
    
    
    
96. CHOI J , Credit K, Henderson K, Deverkadra R, et al
    Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration.
    Clin Cancer Res. 2006;12:1906-12.
    PubMed     Related articles    Abstract available
    
    
    
97. ADAMS GP , Tai MS, McCartney JE, Marks JD, et al
    Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
    Clin Cancer Res. 2006;12:1599-605.
    PubMed     Related articles    Abstract available
    
    
    
98. PIERETTI-VANMARCKE R , Donahoe PK, Szotek P, Manganaro T, et al
    Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo.
    Clin Cancer Res. 2006;12:1593-8.
    PubMed     Related articles    Abstract available
    
    
    February 2006
99. YEN MJ , Hsu CY, Mao TL, Wu TC, et al
    Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma.
    Clin Cancer Res. 2006;12:827-831.
    PubMed     Related articles    Abstract available
    
    
    
100. WAMUNYOKOLI FW , Bonome T, Lee JY, Feltmate CM, et al
     Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
     Clin Cancer Res. 2006;12:690-700.
     PubMed     Related articles    Abstract available
     
     
     November 2005
101. FELTMATE CM , Lee KR, Johnson M, Schorge JO, et al
     Whole-Genome Allelotyping Identified Distinct Loss-of-Heterozygosity Patterns in Mucinous Ovarian and Appendiceal Carcinomas.
     Clin Cancer Res 2005;11:7651-7.
     PubMed     Related articles    Abstract available
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: